What’s with All the Bio M&A in 2019?: A Quick Take
发布时间 2019-02-28 20:56:11 来源
摘要
M&A in the biotech industry is off to a fast start in 2019. Just this past weekend, Roche announced it is acquiring Spark Therapeutics; Ipsen announced its acquisition of Clementia Pharma; and GE announced a spinoff of its biopharma business to Danaher.
Is this all just coincidence... or are there bigger trends at play? In this a16z hallway-style quick-take on recent news, a16z partners Kouki Harasaki (in bio go-to-market) and Nate Chang (in bio corporate development) chat with a16z operating partner Frank Chen about why all this M&A activity is happening now, and what it means for the bio startup ecosystem overall.
GPT-4正在为你翻译摘要中......
